APA (7th ed.) Citation

Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., . . . Stilgenbauer, S. (2018). The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132(23), 2446-2455. https://doi.org/10.1182/blood-2018-05-850461

Chicago Style (17th ed.) Citation

Flinn, Ian W., et al. "The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL." Blood 132, no. 23 (2018): 2446-2455. https://doi.org/10.1182/blood-2018-05-850461.

MLA (9th ed.) Citation

Flinn, Ian W., et al. "The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL." Blood, vol. 132, no. 23, 2018, pp. 2446-2455, https://doi.org/10.1182/blood-2018-05-850461.